A 10‐month angiographic and 4‐year clinical outcome of everolimus‐eluting versus sirolimus‐eluting coronary stents in patients with diabetes mellitus (the diabedES IV randomized angiography trial)

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 7, 2015-12 ,pp. : 1161-1167

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease

By Zhang Feng   Dong Lili   Qian Juying   Ge Junbo  

Annals of Medicine, Vol. 43, Iss. 1, 2011-02 ,pp. : 75-79

Informa Healthcare

Access to resources Recommend Favorite

Rationale and design of amphilimus sirolimus‐eluting stents versus zotarolimus‐eluting stents in all‐comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 410-416

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir‐based polymer‐free amphilimus‐eluting stents versus everolimus‐eluting stents with durable polymer in patients with diabetes mellitus

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. 4, 2015-03 ,pp. : E116-E122

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of Bare-Metal and Sirolimus- or Paclitaxel-Eluting Stents for Aorto-Ostial Coronary Disease

By  

Cardiology, Vol. 111, Iss. 4, 2008-05 ,pp. : 270-276

Karger

Access to resources Recommend Favorite